Considering the role of the integrin αvβ3/PI3K/AKT/SOX2 signaling pathway in FN-induced proliferation, we hypothesized that the combination of integrin αvβ3 inhibitor and chemotherapeutic agents might serve as a potential clinical therapeutic strategy in NSCLC. Here, SOX2 is linked to non-small cell lung carcinoma.